Investor Relations

Galaxy Therapeutics Incorporated brings nature to the bedside. Inspired by the Jellyfish. 

 Galaxy Therapeutics

Galaxy Therapeutics, Inc., based in Milpitas, California. We are an early clinical-stage medical device company that develops
neurovascular devices to treat brain aneurysms.

The Company’s device is developed to increase the success rate of curing the disease. It offers easy deployment and
fluoroscopic visualization and treatment for shallow or large aneurysms, enabling patients to avail improved medical
treatment.  We aim to offer a superior technology currently unavailable to physicians and patients.

Our Saccular Endovascular Aneurysm Lattice treatment (“SEALTM”) technology and the SEALTM embolization device are indicated for endovascular embolization of intracranial, wide-neck bifurcation aneurysms.

We have raised funds through Angel investors and individual investors using SAFE (simple agreement for future equity).  If you are an interested investor please get in touch with us using the link below.  We would be delighted to connect with you and discuss our pitch deck and recent advancements.

Galaxy believes in being good stewards of the investor’s funds and routinely disseminates company progress using investor communication and various social media platforms.

Connect with Galaxy Therapeutics

Galaxy Therapeutics Incorporated brings nature to the bedside.

Key members of the Management team are

Osama Zaidat

President & CEO

Neuroscience and Stroke Medical Director, Bon Secours Mercy Health
St. Vincent Medical Center

Thomas Wolfe

Vice President

Medical Director of Endovascular Surgical Neuroradiology, Aurora St. Luke’s Medical Center

Aamir Badruddin


System Medical Director, Neuroendovascular Surgery 

Edgard Pereira


Interventional Radiology Specialist,
Fawcett Memorial Hospital

Global Neurovascular Devices Market

The global neurovascular devices market was valued at $2.7 billion in 2021 and is expected to reach $2.8 billion in 2022
and $4.5 billion by 2030, growing at a compound annual growth rate (“CAGR”) of 6.0%.
Major factors driving market growth include the introduction of technologically advanced products, the rising adoption of
unhealthy lifestyles, the increasing number of awareness initiatives worldwide, the increasing demand for minimally invasive
procedures, and the increasing prevalence of neurological disorders.

Galaxy Therapeutics is a privately held corporation registered in the State of Delaware. The company has raised and continues to raise funds via Simple Agreement For Equity (SAFE) instruments. The company uses these funds to further its Research and Development, growth of IP Portfolio, Regulatory Compliance, Market Development, and Clinical testing. Galaxy.resolves to an excellent Steward of our investors’s funds and maximize the value creation with responsible use of these funds.